Dysbindin-1 contributes to prefrontal cortical dendritic arbor pathology in schizophrenia

Schizophr Res. 2018 Nov:201:270-277. doi: 10.1016/j.schres.2018.04.042. Epub 2018 May 11.

Abstract

Deep layer III pyramidal cells in the dorsolateral prefrontal cortex (DLPFC) from subjects with schizophrenia and bipolar disorder previously were shown to exhibit dendritic arbor pathology. This study sought to determine whether MARCKS, its regulatory protein dysbindin-1, and two proteins, identified using microarray data, CDC42BPA and ARHGEF6, were associated with dendritic arbor pathology in the DLPFC from schizophrenia and bipolar disorder subjects. Using western blotting, relative protein expression was assessed in the DLPFC (BA 46) grey matter from subjects with schizophrenia (n = 19), bipolar disorder (n = 17) and unaffected control subjects (n = 19). Protein expression data were then correlated with dendritic parameter data obtained previously. MARCKS and dysbindin-1a expression levels did not differ among the three groups. Dysbindin-1b expression was 26% higher in schizophrenia subjects (p = 0.01) and correlated inversely with basilar dendrite length (r = -0.31, p = 0.048) and the number of spines per basilar dendrite (r = -0.31, p = 0.048), but not with dendritic spine density (r = -0.16, p = 0.32). The protein expression of CDC42BPA was 33% higher in schizophrenia subjects (p = 0.03) but, did not correlate with any dendritic parameter (p > 0.05). ARHGEF6 87 kDa isoform expression did not differ among the groups. CDC42BPA expression was not altered in frontal cortex from rats chronically administered haloperidol or clozapine. Dysbindin-1b appears to play a role in dendritic arbor pathology observed previously in the DLPFC in schizophrenia.

Keywords: Bipolar disorder; Dendrite; Dysbindin-1; Postmortem; Schizophrenia; Western blot.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Bipolar Disorder / drug therapy
  • Bipolar Disorder / metabolism
  • Bipolar Disorder / pathology
  • Cohort Studies
  • Dendrites / drug effects
  • Dendrites / metabolism*
  • Dendrites / pathology
  • Disease Models, Animal
  • Dysbindin / metabolism*
  • Female
  • Gene Expression / drug effects
  • Gray Matter / drug effects
  • Gray Matter / metabolism
  • Gray Matter / pathology
  • Humans
  • Male
  • Middle Aged
  • Myotonin-Protein Kinase / metabolism
  • Myristoylated Alanine-Rich C Kinase Substrate / metabolism
  • Prefrontal Cortex / drug effects
  • Prefrontal Cortex / metabolism*
  • Prefrontal Cortex / pathology
  • Protein Isoforms
  • Protein Serine-Threonine Kinases / metabolism
  • Psychotropic Drugs / pharmacology
  • Psychotropic Drugs / therapeutic use
  • Rats
  • Rho Guanine Nucleotide Exchange Factors / metabolism
  • Schizophrenia / drug therapy
  • Schizophrenia / metabolism*
  • Schizophrenia / pathology

Substances

  • ARHGEF6 protein, human
  • DTNBP1 protein, human
  • Dysbindin
  • MARCKS protein, human
  • Protein Isoforms
  • Psychotropic Drugs
  • Rho Guanine Nucleotide Exchange Factors
  • Myristoylated Alanine-Rich C Kinase Substrate
  • CDC42BPA protein, human
  • Cdc42bpa protein, rat
  • Myotonin-Protein Kinase
  • Protein Serine-Threonine Kinases